Avalon Pharmaceutical, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Avalon Pharmaceutical, Inc. - overview
Established
1999
Location
Germantown, MD, US
Primary Industry
Biotechnology
About
Avalon Pharmaceutical, Inc. is a healthcare company focused on developing advanced therapeutic treatments and innovative technology platforms to enhance patient care and clinical outcomes. Founded in 1999 in Germantown, US, Avalon Pharmaceutical, Inc. specializes in healthcare solutions, particularly innovative therapeutic treatments.
The company completed its IPO on September 29, 2005, and has engaged in 8 total deals since its inception. The founder's specific history is not provided. AvalonRx specializes in developing innovative healthcare solutions, focusing on advanced therapeutic treatments and healthcare technology platforms. The company's offerings include proprietary therapies for specific medical conditions and digital health tools that enhance patient engagement and streamline clinical workflows.
AvalonRx caters to hospitals, outpatient clinics, and research institutions in North America and Europe, with a recent expansion into the United States, Canada, Germany, and the United Kingdom. In 2008, AvalonRx reported revenue of USD 311,000 with an EBITDA of USD -20,491,000. The company generates revenue through partnerships with healthcare providers and direct sales to clients, utilizing a subscription model for its digital health platforms and collaborating with distributors for a broader market reach. Avalon Pharmaceutical, Inc.
aims to launch new products and expand into additional markets. The company is targeting new geographic regions for growth, particularly in North America and Europe, following its IPO in September 2005. Recent funding will be utilized to support these initiatives, enhancing their product development and market reach.
Current Investors
PineBridge Investments, EuclidSR Partners, Forward Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.avalonrx.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.